Bioventus Executive and Leadership Team

Anthony Bihl, the Chief Executive Officer at Bioventus, directs the overarching corporate strategy and global market expansion. Overseeing the integration of internal product development with strategic business acquisitions, the Chief Executive Officer ensures alignment with the mission of providing minimally invasive medical treatments. This leadership role involves constant collaboration with the Board to maintain financial health and operational excellence across international markets. By prioritizing innovation in active healing, Anthony Bihl drives the company toward sustainable growth and long-term value creation. The Chief Executive Officer monitors competitive landscapes to identify new distribution agreements that enhance the portfolio of restorative therapies. Through rigorous oversight of organizational performance, Bihl secures the company's position as a leader in the medical manufacturing sector. This executive focus remains fixed on delivering cost-efficient solutions that address critical patient needs while maintaining high standards of clinical efficacy and operational integrity.

Mark Singleton, the Senior VP & Chief Financial Officer at Bioventus, manages all fiscal planning, capital allocation, and financial reporting processes. Overseeing the financial health of the organization, the Senior VP & Chief Financial Officer ensures that resources support the development of innovative medical treatments. This leadership role involves managing investor relations and maintaining transparency regarding the company's economic performance in global markets. By optimizing cost structures and evaluating the financial viability of potential acquisitions, Mark Singleton directly impacts the company's ability to scale operations. The Senior VP & Chief Financial Officer works closely with the executive team to align budgetary goals with the broader mission of enhancing natural healing processes. Through disciplined financial oversight, Singleton mitigates risk and supports the long-term sustainability of the business model. This role remains essential for maintaining the fiscal stability required to bring advanced, minimally invasive therapies to patients worldwide.

Helen Leupold, the Senior Vice President, Chief Human Resources Officer at Bioventus, architects the talent acquisition, organizational development, and corporate culture strategies. Overseeing the recruitment of specialized medical and technical professionals, the Senior Vice President, Chief Human Resources Officer ensures the workforce possesses the expertise necessary to advance active healing innovations. This leadership role involves designing performance management systems that incentivize excellence and align employee contributions with the company's mission. By fostering an inclusive and high-performance environment, Helen Leupold drives engagement across all regional operations. The Senior Vice President, Chief Human Resources Officer collaborates with other C-suite leaders to ensure that human capital initiatives support the company's growth objectives and operational scale. Through strategic workforce planning, Leupold secures the talent pipeline required to maintain a competitive edge in the medical manufacturing industry. This focus on human capital remains central to the company's ability to deliver effective, minimally invasive medical treatments.

Keith McBride, the Chief Technology Officer & Vice President, Research Development Pain & Restorative Therapies at Bioventus, leads the scientific research and product innovation pipeline. Overseeing the development of minimally invasive medical treatments, the Chief Technology Officer & Vice President, Research Development Pain & Restorative Therapies ensures that all new products meet rigorous clinical standards for efficacy. This leadership role involves managing the transition from laboratory research to commercial distribution, focusing specifically on pain and restorative therapy solutions. By directing the technical teams, Keith McBride accelerates the delivery of innovations that engage the body's natural healing processes. The Chief Technology Officer & Vice President, Research Development Pain & Restorative Therapies collaborates with the executive team to align technological advancements with market demands and cost-efficiency goals. Through continuous investment in research, McBride maintains the company's status as a global leader in medical manufacturing. This role remains critical for driving the scientific breakthroughs that define the company's product portfolio.